Halozyme Therapeutics, Inc. $HALO Shares Sold by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 39.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 148,752 shares of the biopharmaceutical company’s stock after selling 97,391 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Halozyme Therapeutics were worth $9,614,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. DLD Asset Management LP boosted its holdings in Halozyme Therapeutics by 20.0% in the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after purchasing an additional 5,000,000 shares during the last quarter. Norges Bank acquired a new stake in Halozyme Therapeutics during the 4th quarter valued at approximately $128,201,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $124,031,000. Voloridge Investment Management LLC purchased a new stake in Halozyme Therapeutics during the 3rd quarter worth approximately $77,587,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $51,295,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the sale, the director owned 43,669 shares of the company’s stock, valued at approximately $2,891,324.49. This trade represents a 3.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $69.07, for a total value of $690,700.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $53,030,564.60. This trade represents a 1.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 93,250 shares of company stock worth $6,299,746 over the last quarter. Insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

HALO has been the subject of several research analyst reports. UBS Group reiterated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $68.55 on Monday. The company has a market cap of $8.13 billion, a PE ratio of 24.66, a P/E/G ratio of 0.28 and a beta of 0.88. Halozyme Therapeutics, Inc. has a fifty-two week low of $51.06 and a fifty-two week high of $82.22. The firm has a 50-day simple moving average of $68.02 and a 200 day simple moving average of $68.64. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter last year, the company posted $1.11 earnings per share. Halozyme Therapeutics’s revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.